BlackRock’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-249,834
| Closed | -$2.84M | – | 5489 |
|
|
2023
Q4 | $2.84M | Buy |
249,834
+212,895
| +576% | +$1.67M | ﹤0.01% | 3903 |
|
|
2023
Q3 | $149K | Sell |
36,939
-136
| -0.4% | -$1.01K | ﹤0.01% | 4753 |
|
|
2023
Q2 | $263K | Sell |
37,075
-5,604
| -13% | -$38.8K | ﹤0.01% | 4664 |
|
|
2023
Q1 | $318K | Sell |
42,679
-15,413
| -27% | -$130K | ﹤0.01% | 4657 |
|
|
2022
Q4 | $422K | Sell |
58,092
-33,303
| -36% | -$281K | ﹤0.01% | 4652 |
|
|
2022
Q3 | $886K | Sell |
91,395
-2,653
| -3% | -$49.5K | ﹤0.01% | 4522 |
|
|
2022
Q2 | $1.8M | Sell |
94,048
-86,921
| -48% | -$2.25M | ﹤0.01% | 4295 |
|
|
2022
Q1 | $8.99M | Buy |
180,969
+9,536
| +6% | +$494K | ﹤0.01% | 3634 |
|
|
2021
Q4 | $12.9M | Sell |
171,433
-1,885
| -1% | -$129K | ﹤0.01% | 3518 |
|
|
2021
Q3 | $13.7M | Buy |
173,318
+1,988
| +1% | +$200K | ﹤0.01% | 3520 |
|
|
2021
Q2 | $23.8M | Buy |
171,330
+4,575
| +3% | +$873K | ﹤0.01% | 3197 |
|
|
2021
Q1 | $34.9M | Buy |
166,755
+30,334
| +22% | +$6.08M | ﹤0.01% | 2850 |
|
|
2020
Q4 | $22.7M | Buy |
136,421
+23,024
| +20% | +$3.56M | ﹤0.01% | 2932 |
|
|
2020
Q3 | $19.3M | Buy |
113,397
+13,285
| +13% | +$1.92M | ﹤0.01% | 2873 |
|
|
2020
Q2 | $16.6M | Buy |
100,112
+19,765
| +25% | +$3.08M | ﹤0.01% | 2899 |
|
|
2020
Q1 | $9.3M | Buy |
80,347
+34,664
| +76% | +$4.87M | ﹤0.01% | 3034 |
|
|
2019
Q4 | $6.76M | Buy |
45,683
+13,484
| +42% | +$2.05M | ﹤0.01% | 3421 |
|
|
2019
Q3 | $4.4M | Buy |
32,199
+2,794
| +10% | +$393K | ﹤0.01% | 3520 |
|
|
2019
Q2 | $3.82M | Buy |
29,405
+20,124
| +217% | +$2.34M | ﹤0.01% | 3601 |
|
|
2019
Q1 | $879K | Buy |
+9,281
| New | +$1.22M | ﹤0.01% | 3951 |
|
BlackRock's HARP Position: Q1 2024 in Review
BlackRock sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 249,834 shares — an estimated $2.84M sold.
BlackRock first reported a position in HARP in Q1 2019 and held it in 20 quarters. The position peaked at $34.9M in Q1 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- BlackRock reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- BlackRock sold 249,834 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.84M.
- BlackRock first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 20 quarters.
- BlackRock's Harpoon Therapeutics, Inc. Common Stock position peaked at $34.9M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.